• Publications
  • Influence
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α
TLDR
Golimumab is a highly stable human monoclonal antibody with high affinity and capacity to neutralize human TNFα in vitro and in vivo and significantly reduced histological scores for arthritis severity and cartilage damage. Expand
Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling.
TLDR
Results strongly suggest that a neutralizing anti-human IL-13 monoclonal antibody could be an effective therapeutic agent for asthma. Expand
Therapeutic Dosing with Anti-Interleukin-13 Monoclonal Antibody Inhibits Asthma Progression in Mice
TLDR
It is demonstrated that neutralization of IL-13 can inhibit the progression of established disease in the presence of repeated allergen exposures and reversed the mucus hyperplasia to basal levels. Expand
Discovery and mechanism of ustekinumab
TLDR
The clinical characterization of ustekinumab continues to clarify the understanding of human immune pathologies and may offer a novel therapeutic option for certain immune-mediated diseases. Expand
Human and Non-Human Primate Intestinal FcRn Expression and Immunoglobulin G Transcytosis
TLDR
In adult primates, FcRn is expressed more highly in distal intestinal epithelial cells, however, mAb delivery to that region results in low serum levels, in part because apical surface F cRn binding does not influence mAb transcytosis. Expand
Chemokine (C-C motif) ligand 2 mediates direct and indirect fibrotic responses in human and murine cultured fibrocytes
TLDR
This study directly compares the functional responses of human and murine fibrocytes to CCR2 ligands, and strengthens the translatability of the murine models to human disease with respect to targeting the C CR2 axis to ameliorate disease in IPF patients. Expand
A novel site contributing to growth-arrest-specific gene 6 binding to its receptors as revealed by a human monoclonal antibody.
TLDR
A neutralizing human monoclonal antibody, named CNTO300, was developed and revealed, for the first time, a second binding site for Gas6-receptor interaction. Expand
CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo
TLDR
CNTO 95 is the first fully human MAb to αv integrins that has potent antitumor and antiangiogenic properties in in vivo preclinical models and a dose‐escalating phase I clinical trial in cancer patients has been initiated. Expand
Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives – an update
TLDR
Analysis of efficacy and safety in the PHOENIX 1 long‐term extension demonstrated that continuous stable maintenance dosing of ustekinumab was generally well tolerated and sustained durable efficacy through up to three years of treatment. Expand
Human framework adaptation of a mouse anti-human IL-13 antibody.
TLDR
Comparisons with m836 putative germline genes suggested interesting analogies between natural affinity maturation and the engineering process that led to the potent HFA anti-human IL-13 antibody. Expand
...
1
2
3
4
5
...